Company Profile
Xeris Pharmaceuticals Stock Price, News & Catalysts
- Ticker:
- XERS
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
8.52 USD (-0.93%)
Close
Last updated: August 17, 2026
1.04B USD
Market cap
Why the stock is moving
As of Aug 17, 2026, XERS closed down 0.93% at $8.52. No new same-company headline was identified in the current news window.
Company overview
Specialty Biopharmaceutical Portfolio
Xeris Biopharma develops and commercializes products across endocrinology and neurology, using formulation technologies to improve administration and treatment reliability.
Endocrine Products
Recorlev is an oral cortisol-synthesis inhibitor for endogenous hypercortisolemia in Cushing's syndrome. Gvoke is a ready-to-use liquid glucagon for severe hypoglycemia. Keveyis is an oral therapy for primary periodic paralysis. Together, the portfolio gives Xeris a multi-product commercial platform serving specialist prescribers and patients with chronic or episodic endocrine disorders.
Future catalysts
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Xeris Pharmaceuticals (XERS)?
Xeris Pharmaceuticals (XERS) most recently closed at 8.52 USD, a -0.93% move versus the previous session.
What is the market cap of Xeris Pharmaceuticals (XERS)?
Xeris Pharmaceuticals currently has a market capitalization of 1.04B USD on BioPharmSignal.
What does Xeris Pharmaceuticals do?
Specialty Biopharmaceutical Portfolio Xeris Biopharma develops and commercializes products across endocrinology and neurology, using formulation technologies to improve administration and treatment reliability. Endocrine Products Recorlev is an oral cortisol-synthesis inhibitor for endogenous hypercortisolemia in Cushing's syndrome. Gvoke is a ready-to-use...
On which exchange is XERS stock listed?
Xeris Pharmaceuticals (XERS) is associated with NASDAQ, United States, Biopharma.
What is Specialty?
Specialty Biopharmaceutical Portfolio Xeris Biopharma develops and commercializes products across endocrinology and neurology, using formulation technologies to improve administration and treatment reliability.
Which conditions is Xeris Pharmaceuticals targeting with Specialty?
Xeris Pharmaceuticals is associated with neurology based on its company overview and current catalyst commentary.
What is Biopharmaceutical?
Specialty Biopharmaceutical Portfolio Xeris Biopharma develops and commercializes products across endocrinology and neurology, using formulation technologies to improve administration and treatment reliability.
What is Portfolio?
Specialty Biopharmaceutical Portfolio Xeris Biopharma develops and commercializes products across endocrinology and neurology, using formulation technologies to improve administration and treatment reliability.